Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

First-Line Therapies in Inflammatory Bowel Disease

Girardin M.a · Manz M.b · Manser C.c · Biedermann L.c · Wanner R.c · Frei P.c · Safroneeva E.d · Mottet C.e, f · Rogler G.c · Schoepfer A.M.e

Author affiliations

aDivision of Gastroenterology and Hepatology, University Hospital Geneva, Geneva, bDivision of Gastroenterology and Hepatology, Claraspital, Basel, cDivision of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, dInstitute of Social and Preventive Medicine, University of Berne, Berne, eDivision of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, Lausanne, and fDivision of Gastroenterology and Hepatology, Hôpital de Neuchâtel, Neuchâtel, Switzerland

Related Articles for ""

Digestion 2012;86(suppl 1):6–10

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: October 05, 2012
Issue release date: October 2012

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 1

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Abstract

Background and Aims: Medical therapy of inflammatory bowel disease (IBD) is becoming more complex, given the increasing choice of drugs to treat Crohn’s disease (CD) and ulcerative colitis (UC). We aimed to summarize the current guidelines for first-line treatments in IBD. Methods: An extensive literature search with focus on the guidelines of the European Crohn’s and Colitis Organisation for the diagnosis and treatment of CD and UC was performed. First-line treatments were defined as the following drug categories: 5-aminosalicylates, budesonide, systemic steroids, azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab and certolizumab pegol. The following drug categories were not included: cyclosporine and tacrolimus (not yet approved by Swissmedic for IBD treatment). Results: Treatment recommendations for the following clinically frequent situations are presented according to disease severity: ileocecal CD, colonic CD, proximal small bowel CD and perianal CD. For UC the following situations are presented: ulcerative proctitis, left-sided colitis and pancolitis. Conclusions: We provide a summary on the use of first-line therapies for clinically frequent situations in patients with CD and UC.

© 2012 S. Karger AG, Basel


References

  1. Scharl M, Rogler G: Inflammatory bowel disease pathogenesis: what is new? Curr Opin Gastroenterol 2012;28:301–309.
  2. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, Rogler G, Schoepfer AM: Frequency and risk factors for extraintestinal manifestations in the Swiss Inflammatory Bowel Disease cohort. Am J Gastroenterol 2011;106:110–119.
  3. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH: Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2008;3:CD000296.
  4. Tromm A, Bunganič I, Tomsová E, Tulassay Z, Lukáš M, Kykal J, Bátovský M, Fixa B, Gabalec L, Safadi R, Kramm HJ, Altorjay I, Löhr H, Koutroubakis I, Bar-Meir S, Stimac D, Schäffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R, International Budenofalk Study Group: Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn’s disease. Gastroenterology 2011;140:425–434.
  5. D’Haens G, Baert F, van Assche G, et al: Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371:660–667.
  6. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929–936.
  7. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M: Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009;1:CD000067.
  8. Feagan BG, Fedorak RN, Irvine EJ, et al: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000;342:1627–1632.
  9. Arora S, Katkov W, Cooley J, et al: Methotrexate in Crohn’s disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724–1729.
  10. Peyrin-Biroulet L, Deltenre P, de Suray N, et al: Efficacy and safety of anti-tumor necrosis factor agents in Crohn’s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644–653.
  11. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D’Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group: Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362:1383–1395.
  12. Dignass A, Van Assche G, Lindsay JO, Lemann M, Söderholm J, Colombel JF, Danese S, D’Hoore A, Gassull M, Gomollon F, Hommes DW, Michetti P, O’Morain C, Oresland T, Windsor A, Stange EF, Travis SPL: The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010;4:28–62.
  13. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J: Predictors of Crohn’s disease. Gastroenterology 2006;130:650–656.
  14. Bell SJ, William AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA: The clinical course of fistulating Crohn’s disease. Aliment Pharmacol Ther 2003;17:1145–1151.
  15. Van Assche G, Dignass A, Reinisch W, van der Woude J, Sturm A, de Vos M, et al: The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis 2010;4:63–101.
    External Resources
  16. Buchanan GN, Halligan S, Bartram CI, Williams AB, Tarroni D, Cohen CR: Clinical examination, endosonography, and MR imaging in preoperative assessment of filstula in ano: comparison with outcome-based reference standard. Radiology 2004;233:674–681.
  17. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P: Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:661–673.
  18. Pearson DC, May GR, Fick GH, Sutherland LR: Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta-analysis. Ann Intern Med 1995;122:132–142.
  19. Present DH, Rutgeerts P, Targan S, et al: Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398–1405.
  20. Sands BE, Anderson FH, Bernstein CN, et al: Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876–885.
  21. Colombel JF, Schwartz DA, Sandborn WJ, et al: Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut 2009;58:940–948.
  22. Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P, Swiss IBDnet: Efficacy and safety of certolizumab pegol in an unselected Crohn’s disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2011;17:1530–1539.
    External Resources
  23. Marshall JK, Irvine EJ: Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995;9:293–300.
  24. Marshall JK, Irvine EJ: Rectal corticosteroids vs. alternative treatment in ulcerative colitis: a meta-analysis. Gut 1997;40:775–781.
  25. Travis SPL, Stange EF, Lemann M, Oresland T, Bemelman WA, Chowers Y, Colombel JF, D’Haens G, Ghosh S, Marteau P, Kruis W, Mortensen NJ, Penninckx F, Gassull M: European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn Colitis 2008;2:24–62.
  26. Mulder CJJ, Fockens P, Meijer JWR, et al: Beclomethasone dipropionate (3mg) vs. 5-aminosalicylic acid (2g) vs. the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;8:549–553.
  27. Sutherland L, MacDonald JK: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;2:CD000543.
  28. Sutherland L, Macdonald JK: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;19:CD000544.
  29. Marteau P, Probert CS, Lindgren S, et al: Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54:960–965.
  30. Timmer A, McDonald JW, Macdonald JK: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;24:CD000478.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: October 05, 2012
Issue release date: October 2012

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 1

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.